Integrative modeling uncovers p21-driven drug resistance and prioritizes therapies for PIK3CA-mutant breast cancer

Abstract Utility of PI3Kα inhibitors like BYL719 is limited by the acquisition of genetic and non-genetic mechanisms of resistance which cause disease recurrence. Several combination therapies based on PI3K inhibition have been proposed, but a way to systematically prioritize them for breast cancer...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Hon Yan Kelvin Yip, Sung-Young Shin, Annabel Chee, Ching-Seng Ang, Fernando J. Rossello, Lee Hwa Wong, Lan K. Nguyen, Antonella Papa
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Nature Portfolio 2024-01-01
Reeks:	npj Precision Oncology
Online toegang:	https://doi.org/10.1038/s41698-024-00496-y
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!